Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
News May 23, 2011
Vermillion, Inc., a molecular diagnostics company, has announced the appointment of Bruce Huebner to its Board of Directors. Mr. Huebner currently serves as Managing Director at LynxCom Partners, LLC - a Healthcare Consulting Firm.
Mr. Huebner has over 35 years of experience in the diagnostic industry, and has been a key member of upper management in a number of clinical diagnostic companies including Hybritech, Inc., Gen-Probe, Inc., Nanogen, Inc. and Osmetech Molecular Diagnostics.
From 1996 to 2002, he was Executive Vice President and Chief Operating Officer of Gen-Probe, Inc. which today is one of the world leaders in the development of nucleic acid tests, including a focus on diagnostic tests for infectious disease that affect women's health.
From 2002 to 2004, Mr. Huebner was President and Chief Operating Officer of Nanogen, Inc., a publicly held nanotechnology/microarray company. From 2005 to 2008, Mr. Huebner, as President of Osmetech, successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace.
Mr. Huebner currently serves on two Boards and has an active consulting business with a focus on cancer diagnostics and personalized medicine.
"We are pleased to welcome Bruce to the board of Vermillion. His vast experience in healthcare and molecular diagnostics will add a critical set of skills and experiences to our board's composition," said Gail Page, CEO and Chairperson.
Page continued, "He has over 35 years of management experience and an in-depth understanding of commercial operations, including a focus on sales and marketing. This will be a great asset to Vermillion as we enter the next phase of market development for OVA1® and begin to plan for the emergence of our PAD program."
"I am pleased to join the Board of Directors of Vermillion," said Bruce Huebner. "Gail and her management team have made major strides in establishing Vermillion as a leading company in the area of cancer diagnostics. OVA1 is an innovative product that provides valuable information to the physician for better patient care. I look forward to helping the management team accelerate the growth of Vermillion."
In addition to serving as a director, Mr. Huebner is expected to lead a special committee of the Board to evaluate the current sales and marketing strategy for OVA1.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
International Conference on Hepatology and Liver Diseases
Jun 10 - Jun 11, 2019